TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3911735
Drug: Both drug
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drug combinations
Study: 18504760
Drug: Gadobutrol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadobutrol (1.0 mmol Gd/mL, 15 mL)
Study: 18504760
Drug: Gadoterate (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadoterate (0.5 mmol Gd/mL, 30 mL)
Study: 14560166
Drug: Psychoeducational parenting
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational parenting program (3 weekly sessions + 1-month booster)
Study: 8898462
Drug: Praziquantel (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (40 mg/kg body weight)
Study: 1716644
Drug: Chlorthalidone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (100 mg PO)
Study: 1716644
Drug: Control (Org
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Org 10172 IV bolus injection of 3250 anti‐Xa units)
Study: 28333351
Drug: Ciprofloxacin (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (dosage not specified) administered from day 0 to day 14
Study: 24268209
Drug: Bivalirudin (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin (0.75 mg/kg bolus followed by 1.75 mg/kg/hour infusion for ≥30 minutes prior to PCI and continued for ≥4 hours at 0.25 mg/kg/hour)
Study: 24268209
Drug: Standard-of-care anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care anticoagulation (heparins at guideline-recommended doses, with or without glycoprotein IIb/IIIa inhibitors)
Study: 16478762
Drug: 2% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lignocaine gel
Study: 7717498
Drug: Lubafax gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubafax gel (Control)
Study: 26954484
Drug: Aged Garlic
Normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged Garlic Extract (AGE) 1200 mg daily for 4 weeks
Study: 17616771
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg Salacia oblonga extract
Study: 17616771
Drug: 480 mg
Normalized name: magaldrate 480 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 480 mg Salacia oblonga extract
Study: 12503274
Drug: Losec, 40
Normalized name: PriLOSEC, 40 mg oral delayed release capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losec, 40 mg (omeprazole)
Study: 12503274
Drug: famotidine, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine, 80 mg (Quamatel)
Study: 9793352
Drug: Intrapleural analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural analgesia with 75 mg of bupivacaine 0.50% administered through a peridural catheter at 8-hour intervals for up to three times
Study: 20642580
Drug: CLA 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLA 4.5 g/day
Study: 17419879
Drug: Plant sterol
Normalized name: plant sterol complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol esters (PSE) in capsule form (1.3 grams of PSE/day)
Study: 9419519
Drug: Spiral CT
Normalized name: Trichinella spiralis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiral CT with 150 ml diatrizoate meglumine
Study: 9419519
Drug: Spiral CT
Normalized name: Trichinella spiralis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiral CT with 75 ml diatrizoate meglumine
Study: 9419519
Drug: Spiral CT
Normalized name: Trichinella spiralis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiral CT with 100 ml diatrizoate meglumine
Study: 9419519
Drug: Dynamic CT
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic CT with 150 ml diatrizoate meglumine
Study: 2098573
Drug: Flurbiprofen 100
Normalized name: flurbiprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 100 mg twice a day for three months
Study: 30718622
Drug: Baduanjin exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baduanjin exercise (5 × 60 min/weekly for 12 weeks)
Study: 25646406
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (70μg/2800 IU cholecalciferol daily for 52 weeks)
Study: 21879101
Drug: Encapsulated caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Encapsulated caffeine (134 mg)
Study: 15716246
Drug: Multifactorial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifactorial intervention (medical, physiotherapy, and occupational therapy)
Study: 31852579
Drug: 6-month treatment
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month treatment
Study: 31852579
Drug: 3-month treatment
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month treatment
Study: 30250407
Drug: Experimental occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental occupational therapy (OT) intervention
Study: 26865854
Drug: ABT 160
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT 160 mg + LPV/r
Study: 26865854
Drug: ABT 320
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT 320 mg + LPV/r
Study: 24881208
Drug: Presurgical nasoalveolar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presurgical nasoalveolar molding (PNAM) treatment prior to operation in group A
Study: 17134960
Drug: Orlistat (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (120 mg three times a day) combined with diet
Study: 2088995
Drug: Oral controlled-release
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral controlled-release morphine (MS Contin Tablets; MSC)
Study: 2088995
Drug: Previous analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous analgesic regimens
Study: 31813658
Drug: Pentosan polysulfate
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan polysulfate sodium (PPS) monotherapy
Study: 28560502
Drug: Infiltration treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration treatment
Study: 24912053
Drug: Strawberry consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strawberry consumption (500 g daily for 30 days)
Study: 22360383
Drug: Sildenafil (thrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (thrice daily for 4 weeks)
Study: 20105143
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment during infancy and childhood
Study: 18767582
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Danazol (medication group)
Study: 12777271
Drug: Long-acting risperidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting risperidone 75 mg
Study: 12777271
Drug: Long-acting risperidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting risperidone (all doses)
Study: 12870776
Drug: Control (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (50 g glucose without guar)
Study: 10554499
Drug: Bolus group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus group (15 micrograms.kg‐1 bolus dose + 0.1 microgram.kg‐1.min‐1 infusion, n = 9)
Study: 10554499
Drug: Non-bolus group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-bolus group (0.1 microgram.kg‐1.min‐1 infusion, n = 8)
Study: 6847336
Drug: Dextroamphetamine, 15
Normalized name: Amphetamine-Dextroamphetamine, 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine, 15 mg/day
Study: 31167875
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and clopidogrel (reference) after PCI
Study: 31167875
Drug: Aspirin (reference)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (reference) after CABG
Study: 31167875
Drug: DAPT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT plus an anticoagulant (Triple Therapy)
Study: 22075192
Drug: Contrast injection
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast injection (ConI)
Study: 9661644
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg metformin, x 3 daily for 2 months
Study: 9661644
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg metformin, x 3 daily for 4-6 months (in 12 women)
Study: 28235705
Drug: Nicotine lozenge
Normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine lozenge administered immediately prior to the stressor
Study: 28235705
Drug: Nicotine lozenge
Normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine lozenge administered 10 minutes prior to the stressor
Study: 28235705
Drug: Nicotine lozenge
Normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine lozenge administered prior to the stressor
Study: 28235705
Drug: Nicotine lozenge
Normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine lozenge administered after the stressor
Study: 22930256
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (rituximab and azathioprine)
Study: 16547531
Drug: Beta-blockers with
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers with vasodilatory properties
Study: 12867587
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg methylprednisolone acetate (MPA)
Study: 10619792
Drug: High-dose CPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose CPB chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) and peripheral blood progenitor cell support (PBPCS)
Study: 10619792
Drug: Standard-dose CPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose CPB chemotherapy (SDC)
Study: 10619792
Drug: Induction CAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction CAF chemotherapy
Study: 10619792
Drug: Prednisone treatment
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone treatment for DPTS
Study: 1629142
Drug: Enalapril (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5-20 mg daily, mean dose 7.2 mg)
Study: 6091248
Drug: ACTH 1‐17
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTH 1‐17 (100 micrograms i.m. daily for 15 days during 6 consecutive months)
Study: 6091248
Drug: Saline (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (placebo injections)
Study: 31200638
Drug: Terlipressin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin infusion (1 mg bolus over 30 min followed by 2 μg/kg/h continuous infusion)
Study: 31200638
Drug: Terlipressin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin infusion and Control (normal saline)
Study: 20808113
Drug: Hormonal replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal replacement therapy, Mediterranean diet, caffeine and alcohol intake as protective factors
Study: 19331578
Drug: 10(6)-cfu CTV-05
Normalized name: Lactobacillus crispatus (CTV-05)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10(6)-cfu CTV-05 capsules inserted intravaginally twice daily for 3 days
Study: 19331578
Drug: 10(8)-cfu CTV-05
Normalized name: Lactobacillus crispatus (CTV-05)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10(8)-cfu CTV-05 capsules inserted intravaginally twice daily for 3 days
Study: 17342295
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg Depo-Medrol
Study: 17342295
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Depo-Medrol
Study: 11672948
Drug: Alcohol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.5 g/kg bodyweight)
Study: 9626212
Drug: CODE (cisplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CODE (cisplatin, vincristine, doxorubicin, etoposide + G-CSF)
Study: 28665340
Drug: Therapy dog
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy dog (TD) exposure (n = 31)
Study: 23243082
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg elemental iron once weekly (group A)
Study: 23243082
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg elemental iron once daily (group B)
Study: 23243082
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml of a natural color additive (control group C)
Study: 17960589
Drug: Individual or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual or no therapy (Control)
Study: 15598063
Drug: Community-based pharmaceutical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based pharmaceutical care for the elderly
Study: 10866043
Drug: Intravenous and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and/or subcutaneous insulin in 29 patients with newly diagnosed type 1 diabetes
Study: 10866043
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin prophylaxis in 14 islet cell antibody-positive relatives
Study: 10866043
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA) plus subcutaneous insulin in 10 newly diagnosed patients
Study: 9349929
Drug: Turbuhaler (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turbuhaler (1.2 mg salbutamol, 12 x 100 micrograms)
Study: 9349929
Drug: Diskus (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diskus (1.2 mg salbutamol, 6 x 200 micrograms)
Study: 27352955
Drug: High adherence
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High adherence (≥80% medication adherence)
Study: 27352955
Drug: Low adherence
Normalized name: dressing,low adherence and wound contact materials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low adherence (<80% medication adherence)
Study: 22976260
Drug: Achillea millefolium
Normalized name: ACHILLEA MILLEFOLIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Achillea millefolium (1.5 g powdered flower, 3 days a week for 2 months)
Study: 12394379
Drug: Lactobacillus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus GG (10 colony-forming units daily)
Study: 1960663
Drug: Formaldehyde-tyrothricin solution
Normalized name: Tyrothricin
DrugBank: Tyrothricin (DB13503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formaldehyde-tyrothricin solution placed in periodontal pockets
Study: 1960663
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution placed in periodontal pockets (Control)
Study: 6452797
Drug: Zimelidine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimelidine 300 mg
Study: 31851385
Drug: Tailored and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored and dose-dense (DD) epirubicin and cyclophosphamide followed by docetaxel + 1 year of adjuvant trastuzumab
Study: 29146647
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment (NOT) consisting of intravenous antibiotics for 48-72 hours, daily blood tests, and ultrasound follow-up, followed by oral antibiotics if discharge criteria are met.
Study: 29146647
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment (NOT)
Study: 22003000
Drug: Trans sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans sodium crocetinate (TSC) at doses above 1.00 mg/kg
Study: 18069698
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (peginterferon alfa‐2a, 180 mg/week, or peginterferon alfa‐2b, 1.5 mg/kg/week, plus ribavirin, 1000‐1200 mg/day) for 48 weeks
Study: 18069698
Drug: Variable treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable treatment (peginterferon alfa‐2a, 180 mg/week, or peginterferon alfa‐2b, 1.5 mg/kg/week, plus ribavirin, 1000‐1200 mg/day) for individualized duration based on HCV RNA negativity at weeks 4, 8, or 12
Study: 18069698
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for patients who first achieved undetectable HCV RNA at weeks 4, 8, or 12
Study: 18069698
Drug: Variable treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable treatment for patients who first achieved undetectable HCV RNA at weeks 4, 8, or 12
Study: 18069698
Drug: Treatment duration
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment duration of 48 weeks versus 24 weeks for RVR patients with baseline viremia >or=400,000 IU/mL
Study: 11948034
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA), 800 mg/d oral suspension for 8 weeks
Study: 9500751
Drug: Salmeterol (42
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (42 microg twice daily for 12 weeks)
Study: 6454366
Drug: Sulfentanil (0.00015,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfentanil (0.00015, 0.0003, 0.0006 mg/kg)
Study: 6454366
Drug: Morphine (0.100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.100, 0.150, 0.200 mg/kg)
Study: 6454366
Drug: Fentanyl (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (not specified dosage)
Study: 6454366
Drug: Sulfentanil, Morphine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfentanil, Morphine, Fentanyl
Study: 27477289
Drug: Antibody-mediated blockade
Normalized name: digoxin antibodies Fab fragments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody-mediated blockade of CD47 and targeting of CD271+ melanoma cells
Study: 21878579
Drug: Celecoxib dosed
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib dosed at 3 mg/kg bid
Study: 21878579
Drug: Celecoxib dosed
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib dosed at 6 mg/kg bid
Study: 21878579
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg bid capsule (or sprinkles) for patients weighing 10 to 25 kg
Study: 21878579
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg bid for patients >25 kg
Study: 18925413
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of salbutamol
Study: 19146755
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug susceptibility testing (DST)
Study: 15718314
Drug: pegfilgrastim 6
Normalized name: PEGFILGRASTIM 6MG/0.6ML DELIVERY KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegfilgrastim 6 mg subcutaneously on day 2 of each 21-day chemotherapy cycle
Study: 7596183
Drug: Chemotherapy protocol
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy protocol adapted from the multicentre German study
Study: 2087879
Drug: CVD 103-HgR
Normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 103-HgR vaccine (5 x 10^8 viable organisms)
Study: 620478
Drug: Oral chlormethiazole
Normalized name: chlormethiazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chlormethiazole
Study: 620478
Drug: Intravenous chlormethiazole
Normalized name: chlormethiazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chlormethiazole
Study: 28826192
Drug: Pridopidine 45
Normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pridopidine 45 mg twice daily (BID)
Study: 19144760
Drug: Avosentan (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avosentan (5, 10, 25, and 50 mg)
Study: 14998845
Drug: Combination regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimen of doxorubicin and docetaxel (60 mg/m2 each)
Study: 14998845
Drug: Alternating regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating regimen of doxorubicin and docetaxel (100 mg/m2 DOC and 75 mg/m2 doxorubicin)
Study: 14998845
Drug: Sequential regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential regimen of doxorubicin and docetaxel (100 mg/m2 DOC and 75 mg/m2 doxorubicin)
Study: 14998845
Drug: Combination regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimen with prophylactic oral ciprofloxacin
Study: 14998845
Drug: Combination regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimen (60 mg/m2 each)
Study: 7862935
Drug: Fluvoxamine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 200 mg per day for 4 weeks
Study: 7862935
Drug: Fluvoxamine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 200 mg per day
Study: 2816246
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of droperidol I.V. (n = 19)
Study: 2816246
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of droperidol I.V. (n = 30)
Study: 2816246
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of droperidol I.V. (n = 32)
Study: 2816246
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (2 ml) (n = 49)
Study: 824860
Drug: amilorid (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: amilorid (10 mg daily, orally) for two days
Study: 824860
Drug: potassium canrenoate
Normalized name: Potassium canrenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: potassium canrenoate (200 mg daily, i.v.) for two days
Study: 824860
Drug: amilorid (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: amilorid (10 mg daily) long-term treatment (up to 14 weeks)
Study: 824860
Drug: spironolactone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: spironolactone (200 mg daily) long-term treatment (up to 14 weeks)
Study: 824860
Drug: chlortalidone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: chlortalidone (50 mg daily) long-term treatment (up to 14 weeks)